Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms

Osawa, Takahiro; Abe, Takashige; Kikuchi, Hiroshi; Matsumoto, Ryuji; Murai, Sachiyo; Nakao, Takafumi; Tanaka, Shinji; Watanabe, Ayu; Shinohara, Nobuo

Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms

Osawa, Takahiro; Abe, Takashige; Kikuchi, Hiroshi et al.

PLoS ONE, 2022, 17(3), e0265230

Permalink : https://hdl.handle.net/2115/86794

このアイテムのアクセス数:439件（2026-03-14 00:14 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1371/journal.pone.0265230			4

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/86794
タイトル	Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms
著者	Osawa, Takahiro ; Abe, Takashige ; Kikuchi, Hiroshi ; Matsumoto, Ryuji ; Murai, Sachiyo ; Nakao, Takafumi ; Tanaka, Shinji ; Watanabe, Ayu ; Shinohara, Nobuo
e-Rad_Researcher 60374443 著者名 Osawa, Takahiro
著者名 Abe, Takashige
著者名 Kikuchi, Hiroshi
著者名 Matsumoto, Ryuji
著者名 Murai, Sachiyo
著者名 Nakao, Takafumi
著者名 Tanaka, Shinji
著者名 Watanabe, Ayu
e-Rad_Researcher 90250422 著者名 Shinohara, Nobuo
言語	英語
発行日	2022-03-15
出版者	PLOS
収録物名	PLoS ONE
巻(号)	17(3)
ページ	e0265230
抄録	Background & nbsp;Immune checkpoint inhibitors (ICIs) are increasingly being used to treat malignancies. Some patients experience immune-related adverse events (irAEs), which may affect any organ/tissue. IrAEs are occasionally fatal and usually have nonspecific symptoms. We developed a three-step application (https://irae-search.com) to provide healthcare professionals with information on the diagnosis, treatment options, and published reports for 38 categories of irAEs encountered in clinical practice.& nbsp;Methods & nbsp;IrAEs reported in >= 5 cases were identified from articles published between October 2018 and August 2020 by searching Japanese (SELIMIC, JAPIC-Q Service, and JMED Plus) and international (MEDLINE, EMBASE, Derwent Drug File) databases. The cases' symptoms were entered into the application to identify irAEs, which were verified using the reported diagnosis, to evaluate the application's sensitivity and specificity.& nbsp;Results & nbsp;Overall, 1209 cases (1067 reports) were analyzed. The three most common categories of irAEs were pituitary or adrenal disorders (14% of cases), skin disorders (13%), and diabetes mellitus (10%). The top three primary diseases were lung cancer (364 cases), melanoma (286 cases), and renal cell carcinoma (218 cases). The average sensitivity was 90.8% (range 44.4%-100.0%) initially, and improved to 94.8% (range 83.3%-100.0%) after incorporating the symptoms reported in published cases into the application's logic for two irAE categories. The average specificity was 79.3% (range 59.1% [thyroid disorders]-98.2% [arthritis]).& nbsp;Conclusion & nbsp;irAE Search is an easy-to-use application designed to help healthcare professionals identify potential irAEs in ICI-treated patients in a timely manner to facilitate prompt management/treatment. The application showed high sensitivity and moderate-to-high specificity for detecting irAEs.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1932-6203
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1371/journal.pone.0265230